1
|
Jericevic D, Shapiro K, Bowman M, Vélez CA, Mbassa R, Fang R, Van Kuiken M, Brucker BM. Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry. Urol Pract 2024; 11:394-401. [PMID: 38226920 DOI: 10.1097/upj.0000000000000496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 11/02/2023] [Indexed: 01/17/2024]
Abstract
INTRODUCTION Overactive bladder (OAB) patients who do not achieve satisfactory results with second-line OAB medications should be offered third-line therapies (percutaneous tibial nerve stimulation, sacral neuromodulation, onabotulinumtoxinA bladder injection [BTX-A]). We aimed to determine which clinical factors affect progression from second- to third-line OAB therapy. METHODS Between 2014 and 2020, the AUA Quality Registry was queried for adult patients with idiopathic OAB. For the primary outcome, patient and provider factors associated with increased odds of progression from second- to third-line therapy were assessed. Secondary outcomes included median time for progression to third-line therapy and third-line therapy utilization across subgroups. RESULTS A total of 641,122 patients met inclusion criteria and were included in analysis. Of these, only 7487 (1.2%) received third-line therapy after receiving second-line therapy. On multivariate analysis, patients aged 65 to 79, women, White race, history of dual anticholinergic and β3 agonist therapy, metropolitan area, government insurance, and single specialty practice had the greatest odds of progressing to third-line therapy. Black and Asian race, male gender, and rural setting had lower odds of progressing to third-line therapy. BTX-A was the most common therapy overall (40% BTX-A, 32% sacral neuromodulation, 28% percutaneous tibial nerve stimulation). The median time of progression from second- to third-line therapy was 15.4 months (IQR 5.9, 32.4). Patients < 50 years old and women progressed fastest to third-line therapy. CONCLUSIONS Very few patients received third-line therapies, and the time to progression from second- to third-line therapies is > 1 year. The study findings highlight a potential need to improve third-line therapy implementation.
Collapse
Affiliation(s)
- Dora Jericevic
- Department of Urology, New York University Langone, New York, New York
| | - Katherine Shapiro
- Department of Urology, New York University Langone, New York, New York
| | - Max Bowman
- Department of Urology, University of California San Francisco, San Francisco, California
| | - Camille A Vélez
- Universidad Central del Caribe, School of Medicine, Bayamon, Puerto Rico
| | - Rachel Mbassa
- American Urological Association, Linthicum, Maryland
| | - Raymond Fang
- American Urological Association, Linthicum, Maryland
| | - Michelle Van Kuiken
- Department of Urology, University of California San Francisco, San Francisco, California
| | | |
Collapse
|
2
|
LaPier Z, Jericevic D, Lang D, Gregg S, Brucker B, Escobar C. Predictors of Care-Seeking Behavior for Treatment of Urinary Incontinence in Women. Urogynecology (Phila) 2024; 30:352-362. [PMID: 38484253 DOI: 10.1097/spv.0000000000001491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2024]
Abstract
IMPORTANCE Urinary incontinence (UI) is a common and treatable medical condition among women, but only approximately one third of women seek care. OBJECTIVE The objective of this study was to determine factors associated with care-seeking behavior in women with UI. STUDY DESIGN This was a cross-sectional study using patient-reported survey data collected by the National Association for Continence from November 2018 to January 2019. This survey included 60 questions and was conducted using SurveyMonkey. Descriptive statistics were used for baseline characteristics, the χ2 test was used for categorical variables, and multivariate logistic regression was used to determine predictors of care-seeking behavior. RESULTS Four hundred eighty-five women completed the survey, 30.7% were not care seeking, and 69.3% were care seeking for UI. Most women were 55 years or older and had UI for more than 4 years. Care-seeking women had more overactive bladder symptoms. Women who sought care were more likely to report feelings of anger, depression, hopelessness, isolation, and report greater social effects from UI than non-care-seeking women. Less than 10% of women who sought care were asked about their UI by a medical professional. In the multivariate logistic regression expenditure of $5 or more on monthly incontinence maintenance, daily UI and older age were associated with seeking care. CONCLUSIONS Most women in our study population sought care for UI. Factors associated with seeking care were expenditure greater than $5 per month on incontinence, daily UI, and age. This information demonstrates the need for effective implementation of screening interventions to increase treatment access.
Collapse
Affiliation(s)
| | | | - Diane Lang
- Obstetrics and Gynecology, NYU Grossman School of Medicine, New York, NY
| | - Steven Gregg
- National Association for Continence, Charleston, SC
| | | | | |
Collapse
|
3
|
Bowman M, Vélez CA, Jericevic D, Shapiro K, Mbassa R, Fang R, Brucker BM, Van Kuiken M. Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry. Urology 2024; 184:51-57. [PMID: 38081481 DOI: 10.1016/j.urology.2023.11.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 11/14/2023] [Accepted: 11/22/2023] [Indexed: 12/24/2023]
Abstract
OBJECTIVE To determine how a patient's demographics, including insurance type, race/ethnicity, gender, and age, may impact the choice of medication prescribed for overactive bladder (OAB). METHODS We queried the AUA Quality Registry for adults between 2014 and 2020 with a diagnosis of OAB for >1year, excluding neurogenic causes. Variables included age, race/ethnicity, gender, insurance type, medication first prescribed, year of prescription, provider metropolitan status, and provider practice type. Primary outcome was which factors were associated with increased odds of beta-3 prescription as first medication choice. RESULTS We found 1,453,566 patients with OAB, 641,122 (44.1%) with complete data. Of these, 112,021 (17.5%) were prescribed medication. On multivariate analysis, patients with Medicaid, Medicare, and other/self-pay insurance were less likely to receive a beta-3 vs an anticholinergic compared to private or military insurance. Compared to white patients, Asian, Black, and other races were less likely to receive a beta-3, as were patients outside of metropolitan areas. Age >50, prescriptions after 2014, and nonacademic settings were associated with increased odds of beta-3 prescription. There was no difference between genders. CONCLUSION Many nonclinical factors, including insurance type and race, may affect which medication is first prescribed for OAB. This is useful for practicing urologists and may help lower barriers to beta-3 prescription through policy change and advocacy.
Collapse
Affiliation(s)
- Max Bowman
- University of California San Francisco, Department of Urology, San Francisco, CA.
| | - Camille A Vélez
- Universidad Central del Caribe, School of Medicine, Bayamon, PR
| | - Dora Jericevic
- New York University Langone, Department of Urology, New York, NY
| | | | | | | | | | - Michelle Van Kuiken
- University of California San Francisco, Department of Urology, San Francisco, CA
| |
Collapse
|
4
|
Jericevic D, Brucker B. Telemedicine in Overactive Bladder Syndrome. Curr Bladder Dysfunct Rep 2023; 18:103-108. [PMID: 37193335 PMCID: PMC10015147 DOI: 10.1007/s11884-023-00689-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/10/2023] [Indexed: 03/17/2023]
Abstract
Purpose of Review This review discusses the role and benefits of telemedicine as an integral component of the post-pandemic care paradigm in urological practice and, in particular, as part of the care of patients with overactive bladder (OAB). Recent Findings The COVID-19 pandemic accelerated the implementation of telemedicine across almost every medical specialty and (at least temporarily) swept away barriers including those regarding reimbursement and licensure. Telemedicine benefits patients and providers alike including savings on transportation costs, access to specialists or tertiary care from geographically remote locations, and minimized exposure to a contagious illness. Integration of telemedicine into clinical practice can reduce costs for office/exam space and staffing overhead, as well as facilitate greater scheduling efficiency. Many, if not most, aspects of care for the uncomplicated OAB patient can be as effectively managed remotely as with in-person encounters, across the treatment algorithm. Summary Telemedicine will almost certainly remain a key component in the care of OAB, general urology, and throughout all medical specialties.
Collapse
Affiliation(s)
- Dora Jericevic
- Departments of Urology and Obstetrics & Gynecology, New York University Langone Health, New York, NY USA
| | - Benjamin Brucker
- Departments of Urology and Obstetrics & Gynecology, New York University Langone Health, New York, NY USA
| |
Collapse
|
5
|
Sussman RD, Escobar C, Jericevic D, Oh C, Arslan A, Palmerola R, Pape DM, Smilen SW, Nitti VW, Rosenblum N, Brucker BM. Estimation of Urinary Frequency: Does Question Phrasing Matter? Urology 2021; 156:90-95. [PMID: 33901531 DOI: 10.1016/j.urology.2021.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 04/09/2021] [Accepted: 04/12/2021] [Indexed: 12/14/2022]
Abstract
PURPOSE To evaluate if question phrasing and patient numeracy impact estimation of urinary frequency. MATERIALS AND METHODS We conducted a prospective study looking at reliability of a patient interview in assessing urinary frequency. Prior to completing a voiding diary, patients estimated daytime, and nighttime frequency in 3 ways: (1) how many times they urinated (2) how many hours they waited in between urinations (3) how many times they urinated over the course of 4 hours. Numeracy was assessed using the Lipkus Numeracy Scale. RESULTS Seventy-one patients completed the study. Correlation of estimates from questions 1, 2, and 3 to the diary were not statistically different. Prediction of nighttime frequency was better than daytime for all questions (correlation coefficients 0.751, 0.754, and 0.670 vs 0.596, 0.575, and 0.460). When compared to the diary, Question 1 underestimated (8.5 vs 9.7, P = .014) while Question 2 overestimated (11.8 vs 9.7, P = .027) recorded voids on a diary. All questions overpredicted nighttime frequency with 2.6, 2.9, and 3.9 predicted versus 1.6 recorded voids (P < .001). Although not statistically significant, for each question, the predicted frequency of numerate patients was more correlated to the diary than those of innumerate patients. CONCLUSION When compared to a voiding diary for daytime urinary frequency, asking patients how many times they urinated underestimated, and asking patients how many hours they waited between urinations overestimated the number recorded voids. Regardless of phrasing, patients overestimated nighttime urination. Patients in our functional urology population have limited numeracy, which may impact accuracy of urinary frequency estimation.
Collapse
Affiliation(s)
- Rachael D Sussman
- Department of Urology, New York University Medical Center, New York, NY.
| | - Christina Escobar
- Department of Urology, New York University Medical Center, New York, NY
| | - Dora Jericevic
- Department of Urology, New York University Medical Center, New York, NY
| | - Cheonguen Oh
- Departments of Population Health and Environmental Medicine, New York University Medical Center, New York, NY
| | - Alan Arslan
- Departments of Population Health, Environmental Medicine & Obstetrics and Gynecology New York University Medical Center, New York, NY
| | - Ricardo Palmerola
- Department of Urology, New York University Medical Center, New York, NY
| | - Dominique M Pape
- Department of Urology, New York University Medical Center, New York, NY
| | - Scott W Smilen
- Department of Obstetrics and Gynecology, Hackensack Meridian Health Jersey Shore University Medical Center, Neptune City, NJ
| | - Victor W Nitti
- Department of Urology, UCLA Medical Center, Santa Monica, CA
| | - Nirit Rosenblum
- Department of Urology, New York University Medical Center, New York, NY
| | | |
Collapse
|
6
|
Brucker BM, Jericevic D, Rude T, Enemchukwu E, Pape D, Rosenblum N, Charlson ER, Zhovtis-Ryerson L, Howard J, Krupp L, Peyronnet B. Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study. Urology 2020; 145:94-99. [PMID: 32822687 DOI: 10.1016/j.urology.2020.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 08/04/2020] [Accepted: 08/06/2020] [Indexed: 12/22/2022]
Abstract
OBJECTIVE To determine the patient-perceived effectiveness and tolerability of mirabegron compared to solifenacin in a multiple sclerosis (MS) population with overactive bladder (OAB) symptoms. MATERIALS AND METHODS MS patients with OAB symptoms who were not on medication for their urinary symptoms at enrollment were prospectively recruited. Patients enrolled in years 1-2 were prescribed mirabegron, whereas patients enrolled in years 3-4 were prescribed solifenacin. At enrollment and 6-week follow-up, patients completed several patient reported outcome measures. The primary outcome was change in OAB Questionnaire Short Form (OAB-q SF) symptom severity and minimal clinically important difference (MCID) achievement. The Patient Assessment of Constipation Symptoms (PAC-SYM) was used to assess bowel function over the treatment period. RESULTS Sixty-one patients were enrolled. The majority of the mirabegron (70%) and the solifenacin (69%) group achieved the OAB-q SF symptom severity MCID. The solifenacin group had a statistically significant greater decrease in its end of study OAB-q SF score (Δ = -37.87 vs -20.43, P = .02). Constipation improved in the mirabegron group and worsened in the solifenacin group (ΔPAC-SYM = -0.38 vs +0.22; P = .02), with 30% of patients prescribed solifenacin experiencing worsening above the MCID threshold. CONCLUSION Among MS patients, we demonstrated similar response rates to mirabegron and solifenacin, with approximately 50%-70% achieving each patient reported outcome measure's MCID. Though this small study showed some short-term evidence that improvement in urinary symptom severity was greater with solifenacin, this potential benefit must be weighed against the observed risk of worsening constipation. Further studies are needed to confirm these findings.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Lauren Krupp
- New York University Langone Health, New York, NY
| | | |
Collapse
|
7
|
Abstract
Despite advances in systemic therapy and immunotherapy, surgery continues to have a role in management of advanced renal cell carcinoma (aRCC). Minimally invasive surgery (MIS) is considered standard of care for smaller, localized tumors due to faster recovery without compromising oncologic outcomes. There are concerns about MIS for aRCC due to a potential risk of inferior oncologic outcomes and unusual patterns of disease recurrence. Recent studies, however, suggest that in properly selected patients with aRCC, MIS can provide improved peri-operative outcomes without compromising oncologic control.
Collapse
Affiliation(s)
- Ezequiel Becher
- Department of Urology, NYU Langone Health, 222 East 41st, 12th Floor, New York, NY 10017, USA.
| | - Dora Jericevic
- Department of Urology, NYU Langone Health, 222 East 41st, 12th Floor, New York, NY 10017, USA
| | - William C Huang
- Department of Urology, NYU Langone Health, 222 East 41st, 12th Floor, New York, NY 10017, USA
| |
Collapse
|
8
|
Peyronnet B, Jericevic D, Rude T, Ekenchukwu E, Sussman R, Palmerola R, Pape D, Escobar C, Zhovtis L, Howard J, Charlson R, Krupp L, Rosenblum N, Nitti V, Brucker B. Comparaison prospective non randomisée de la solifenacine et du mirabegron chez les patients atteints de sclérose en plaques ayant des symptômes d’hyperactivité vésicale. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
|
10
|
|